Vivia Biotech

Executive Summary

Vivia Biotech is a preclinical and translational Contract Research Organization (CRO) based in Madrid, Spain, specializing in ex vivo functional drug testing, biomarker discovery, and bioinformatic analysis. Its proprietary platform preserves the native tumor and immune microenvironment, providing clinically relevant data for oncology and autoimmune drug development. Founded in 2019, the company serves pharmaceutical and biotech clients seeking to de-risk early-stage drug programs. As a private, pre-clinical stage CRO, Vivia Biotech's value proposition lies in its ability to generate high-fidelity ex vivo data that can bridge preclinical and clinical outcomes. The company has not disclosed funding rounds, valuation, or commercialization milestones, indicating an early growth phase. The Spanish CRO market is competitive but Vivia's niche in preserving native microenvironments could differentiate it. Key risks include limited scalability and reliance on client contracts for revenue.

Upcoming Catalysts (preview)

• Q4 2026Announcement of Major Client Partnership or Contract40% success
• H2 2027Expansion of Platform into New Indications (e.g., rare diseases, inflammation)30% success
• Q1 2027Publication of Validation Study in Peer-Reviewed Journal50% success